#Incyte
Steven H Stein (CMO & Head of Late-Stage Dev.) sold $28.4M of Incyte (INCY).

Executed Nov 6, disclosed Nov 10. Four days.

paydirt.news/filing/246473/steven-h-stein-sold-incy

$INCY #insidertrading #stocks #trading
Steven H Stein (CMO & Head of Late-Stage Dev.) sold $28.4M of Incyte (INCY). · Paydirt
Executed Nov 6, disclosed Nov 10. Four days. The filing, the filer's record, and the original document on Paydirt.
paydirt.news
November 10, 2026 at 10:08 PM
Incyte Corp. alleged that Granules India Ltd. infringes five patents through its proposed generic of a treatment for myelofibrosis, a type of blood cancer.
Incyte Sues Generic Manufacturer Over Blood Cancer Drug Patents
Incyte Corp. alleged that Granules India Ltd. infringes five patents through its proposed generic of a treatment for myelofibrosis, a type of blood cancer.
bit.ly
November 8, 2026 at 3:00 PM
$INCY Incyte: revenue up 14% to $1.56B, 2026 sales guidance raised (Q3 2026)
Hub: https://www.merlintrader.com/incyte-incy-stock-hub/?utm_source=bluesky&utm_medium=social&utm_campaign=flyer-q3-2026&utm_content=incy

Not investment advice.
November 10, 2026 at 10:40 PM
$TEVA +1.98%, $LMB +2.08%, $INCY +1.64%, $MDLN +3.06%, $NBIX +3.12% all closed above classic pivot R1.

All rank top 1% quality. Teva targeting $6-7B innovative revenue by 2030; Incyte in new Phase II cancer trial.

#technicalanalysis #stocks
November 11, 2026 at 11:20 PM
The trial will evaluate Incyte’s investigational bispecific immunotherapy in patients with stage 2/3 CRC who have completed surgery and adjuvant chemotherapy.
Natera, Incyte Collaborate on Interventional Phase II Study in Colorectal Cancer
Natera, Incyte Collaborate on Interventional Phase II Study in Colorectal Cancer
ebx.sh
November 10, 2026 at 8:45 PM
🔴 #$INCY — Clinical Milestone
Phase 3 MAESTRA-3 Cancelled - INCB123667 in 1L Maintenance Ovarian Cancer
Incyte decided not to proceed with the planned Phase 3 MAESTRA-3 study of INCB123667 plus bevacizumab in first-line maintenance ovarian cancer, which had bee…

https://biostock.app/symbols/INCY
November 13, 2026 at 9:20 PM
Incyte ($INCY) – Insider Sale

• Insider: Steven H Stein, CMO & Head of Late-Stage Dev.
• Sold: 240,193 shares (about $28M)
• Price: about $118.39 a share · Nov 6
• Plan: pre-set 10b5-1 sale plan

📊 More at www.elixstocks.com

Educational only. Not investment advice.

#InsiderSelling #Stocks
Steven H Stein (CMO & Head of Late-Stage Dev.) sold $28M of Incyte ($INCY)
Form 4 filed Nov 10. Every line of the filing.
elixstocks.com
November 11, 2026 at 1:51 PM
Wed news: Analysis suggests US bid to increase German drug prices will raise costs for both. Natera and Incyte partner on colorectal cancer trial. FDA has over 1k open jobs — and the staffing shortage is hitting pharma. Amgen Sjögren’s trial win. —https://bit.ly/3JeBlY5
November 11, 2026 at 5:37 PM
November 9, 2026 at 4:20 PM
#$INCY options: $370K in premium, $346K in calls and $24K in puts (94% calls).
Biggest unusual trade: 600 call contracts expiring Mar 19, $153K in premium vs 51 open interest.

Full story at the link.
#optionsflow #stocks #optionstrading #stockmarket
Incyte (INCY) Technical Levels: Options Flow, Dark Pools Line Up Above $119
INCY at $122.27: support $119.46, resistance $123.96; the chart, options flow and dark pools line up bullish.
globaltradersacademy.com
November 12, 2026 at 3:15 AM
ALERT 🚨: Stein Steven H, CMO & Head of Late-Stage Dev., sold $8.81M of INCYTE CORP (INCY) on 2026-11-06. Stein Steven H, CMO & Head of...

https://www.narrowit.com/sec/filing?cik=0000879169&accession=0001673776-26-000022&doc=xslF345X06%2Fwk-form4_1794344840.xml
#SEC #Form4 #InsiderTrading #INCY
Insider Trading | Narrowit.com
Insider Trading for SEC accession 0001673776 26 000022 with readable ownership transactions, filing details, and source document access.
www.narrowit.com
November 11, 2026 at 1:05 AM
#$INCY: Dark pool shares by session (share of volume): Nov 10 619,353 (34.5%).
Off-exchange volume Nov 10 was 0.9x the usual, trend fading over 5 sessions.

Read the full article for the full details.
#darkpool #stocks #fintwit
Dark Pool Check: Incyte (INCY)
GTA's dark-pool check on INCY: how much traded off the exchanges against its own normal, the last five sessions, and the options lean.
globaltradersacademy.com
November 10, 2026 at 11:05 PM
📄 #INCY 10-Q — what changed
MD&A now says: "Management's Discussion and Analysis of Financial Condition and Results of Operations The following discussion of our financial condition and results of operations as of and for the three and nine months ended September 30, 2026 should be read in conjunct
FormDelta — Insider Trading Alerts
What INCYTE CORP changed in their own words, quarter over quarter.
www.formdelta.com
November 10, 2026 at 9:08 PM
Check out this new ad for vitiligo awareness from Incyte in France adph.ws/p/187535 #CreativeIntelligence #CompetitiveIntelligence #HealthcareAdvertising
November 6, 2026 at 5:11 PM
Incyte Corp. alleged that Granules India Ltd. infringes five patents through its proposed generic of a treatment for myelofibrosis, a type of blood cancer.
Incyte Sues Generic Manufacturer Over Blood Cancer Drug Patents
Incyte Corp. alleged that Granules India Ltd. infringes five patents through its proposed generic of a treatment for myelofibrosis, a type of blood cancer.
bit.ly
November 6, 2026 at 1:30 AM
#ConSaludTV | Incyte acelera su apuesta oncológica con cinco programas en fase III y nuevas terapias para varios tipos de cáncer

Incyte acelera el desarrollo de nuevas terapias contra el cáncer: “Lo que prometimos hace dos años se está convirtiendo en realidad ”
Lee Heeson, Executive Vice President, Head of Incyte International, destaca el potencial de su cartera oncológica y la importancia de mejorar el diagnóstico molecular para facilitar el acceso a tratamientos dirigidos.
www.consalud.es
November 5, 2026 at 10:31 AM
Incyte $INCY: Leerink Partners lowered its price target from $154.00 to $150.00 and maintained its Outperform rating.

https://fundspec.ai/s/INCY/analysts
Stress test revenue, margin and WACC to see the real upside and downside.
November 5, 2026 at 9:45 PM
Chronic Hand Eczema Pipeline Analysis 2026: Phase III and Phase II Assets, MOA Breakdown, and Route of Administration Trends | Incyte Corp, LEO Pharma, Asana BioSciences, Arcutis Biotherapeutics
https://www.pressreleasecc.com/2026/11/03/chronic-hand-eczema-pipeline-analysis-2026-phase-iii-and-phase-ii-assets-moa-breakdown-and-route-of-administration-trends-incyte-corp-leo-pharma-asana-biosciences-arcutis-biotherapeutics
www.pressreleasecc.com
November 4, 2026 at 11:12 AM
#$INCY weekly close $120.39 (+4.0% w/w), below SMA50 $120.49 / above SMA200 $108.06, RSI 57.5. Support $107.78, resistance $122.87.

Oct 29: Q3 total revenue $1.56B (+14% y/y); 2026 net sales guidance raised.

New hub updated: www.merlintrader.com/incyte-incy-...
November 1, 2026 at 1:44 PM